In a phase-III study in Japan, the „TransDermaSal“ technology of the company, a transdermal drug delivery system based on a systemic tape and doped with a second-generation antihistamine, proved superior to oral administration of the same antihistamine.

Hisamitsu Pharmaceuticals news release, July 25, 2016